CN112121152A - Application of linatide in preparation of antitumor drugs - Google Patents
Application of linatide in preparation of antitumor drugs Download PDFInfo
- Publication number
- CN112121152A CN112121152A CN202011028623.1A CN202011028623A CN112121152A CN 112121152 A CN112121152 A CN 112121152A CN 202011028623 A CN202011028623 A CN 202011028623A CN 112121152 A CN112121152 A CN 112121152A
- Authority
- CN
- China
- Prior art keywords
- linatide
- tumor
- mice
- immune activation
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 5
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 94
- 230000005934 immune activation Effects 0.000 claims abstract description 56
- 239000003814 drug Substances 0.000 claims abstract description 45
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract description 25
- 102000008070 Interferon-gamma Human genes 0.000 claims abstract description 25
- 229960003130 interferon gamma Drugs 0.000 claims abstract description 25
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 23
- 230000004083 survival effect Effects 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 206010061289 metastatic neoplasm Diseases 0.000 claims abstract description 10
- 230000001394 metastastic effect Effects 0.000 claims abstract description 9
- 230000000306 recurrent effect Effects 0.000 claims abstract description 9
- 210000002865 immune cell Anatomy 0.000 claims abstract description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 21
- 208000026310 Breast neoplasm Diseases 0.000 claims description 20
- 230000028327 secretion Effects 0.000 claims description 16
- 201000001441 melanoma Diseases 0.000 claims description 15
- 206010009944 Colon cancer Diseases 0.000 claims description 14
- 208000029742 colonic neoplasm Diseases 0.000 claims description 14
- 230000002980 postoperative effect Effects 0.000 claims description 5
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 59
- 238000011282 treatment Methods 0.000 abstract description 50
- 230000000694 effects Effects 0.000 abstract description 47
- 238000001727 in vivo Methods 0.000 abstract description 34
- 238000011398 antitumor immunotherapy Methods 0.000 abstract description 23
- 241001465754 Metazoa Species 0.000 abstract description 10
- 230000004614 tumor growth Effects 0.000 abstract description 9
- 230000035755 proliferation Effects 0.000 abstract description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 46
- 230000006870 function Effects 0.000 description 35
- 229960001534 risperidone Drugs 0.000 description 30
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 29
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 20
- 238000000338 in vitro Methods 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 238000010254 subcutaneous injection Methods 0.000 description 15
- 239000007929 subcutaneous injection Substances 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 10
- 230000036039 immunity Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 6
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 6
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 6
- 102100040918 Pro-glucagon Human genes 0.000 description 6
- 230000001610 euglycemic effect Effects 0.000 description 6
- 108010004367 lixisenatide Proteins 0.000 description 6
- 229960001093 lixisenatide Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 5
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 5
- 206010061598 Immunodeficiency Diseases 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000001019 normoglycemic effect Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011510 Elispot assay Methods 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000005809 anti-tumor immunity Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000001024 immunotherapeutic effect Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the field of tumor treatment, in particular to application of linatide in preparation of antitumor drugs. The invention discloses the effect of the linatide on immune activation and the effect on anti-tumor immune activation; also discloses the function of the linatide in the aspect of anti-tumor immunotherapy. The results of the invention show that the linatide can significantly stimulate the proliferation of immune cells, and can significantly stimulate the release of interferon gamma (IFN-gamma); the linatide can obviously inhibit the growth of tumors and obviously prolong the life cycle of tumor-bearing mice on a plurality of in vivo animal tumor-bearing models; the linatide can obviously prolong the survival period of mice after metastatic recurrent tumor operations, and the safety of the linatide is basically ensured because the linatide is a drug on the market. In conclusion, the linatide can be used for preparing antitumor drugs.
Description
Technical Field
The invention relates to the field of tumor treatment, in particular to an immune activation effect and an anti-tumor application of linatide.
Background
Tumors are a serious disease threatening the health of humans. The traditional schemes of surgery, radiotherapy, chemotherapy and the like inhibit the progress of tumors to a certain extent, but the relapse and the metastasis of the tumors are difficult to control. With the ever-rising exciting clinical findings, anti-tumor immunotherapy holds promise for tumor patients. The immune system has the capacity of identifying and eliminating heterosis, and tumors can inhibit the innate immune response of the immune system through various ways in the occurrence and development process, and can paralyze infiltrated immune effector cells by limiting the display of self novel antigens, starting immune check points and other methods, thereby achieving the purpose of avoiding immune identification and immune elimination. How to effectively activate anti-tumor immune response and relieve immune evasion so as to achieve the effect of immune elimination is always a goal pursued in the field of tumor immunotherapy.
Glucagon-like peptide-1 (GLP-1) is an endogenous polypeptide secreted by human body, and is a peptide hormone of 30 amino acids obtained by tissue-specific post-translational processing of glucagon gene. GLP-1 can stimulate insulin secretion by binding with its receptor GLP-1R, and has blood glucose lowering effect. GLP-1 can also produce weight loss effects through a variety of pathways, including inhibition of gastrointestinal motility and gastric secretion, inhibition of appetite and feeding, delay of gastric emptying, and the like. In addition, GLP-1 acts on the central nervous system (especially the hypothalamus), thereby causing satiety and reducing appetite in humans. GLP-1 also has many physiological functions, such as lowering blood lipid, lowering blood pressure, protecting the cardiovascular system, enhancing learning and memory functions, protecting nerves, etc., by acting on the center. So far, no report of immune activation or anti-tumor immune activation exists.
GLP-1 has extremely short half-life of only 1.5-2 minutes, and cannot be clinically used for treating diabetes and other diseases. Therefore, the pharmaceutical field is trying to develop synthetic agonists of glucagon-like peptide-1 receptor (GLP-1R) with long half-life, and it is expected that GLP-1 similar activity and function will be obtained while prolonging half-life.
Linatide (rivastigmine) is a novel glucagon-like peptide-1 (GLP-1) receptor agonist. It is an artificially synthesized agonist of glucagon-like peptide-1 receptor (GLP-1R) developed by the company Sonofuran.
There has been no report of the use of risperidone for tumor therapy or anti-tumor, nor data or results of its immune activation or anti-tumor immune activation. When a polypeptide drug with an immune activation function is screened, the polypeptide drug is found to have an unexpected function, namely immune activation effect, so that the polypeptide drug is tried to be applied to anti-tumor immune activation and anti-tumor immunotherapy.
Disclosure of Invention
The invention aims to disclose the immune activation activity of the linatide and the application of the linatide in preparing an activated anti-tumor immune medicament through in vitro research; the immune activation effect of the linatide and the application of the linatide in preparing anti-tumor immunotherapy medicaments are confirmed through a plurality of in vivo animal models.
The invention confirms the application of the linatide in preparing the immune activation medicine in vitro. Furthermore, the invention confirms the application of the linatide in preparing anti-tumor immune activation medicaments on a plurality of in-vivo models, and confirms the application of the linatide in preparing anti-tumor immune treatment medicaments in vivo. At the same time, the basic safety of the linatide was also confirmed.
The invention is summarized as follows:
(1) the linatide can obviously stimulate the proliferation of immune cells in vitro and the release of interferon gamma (IFN-gamma), has definite immune activation effect, and discloses the application of the linatide in preparing immune activation medicaments.
(2) The linatide can remarkably stimulate the release of interferon gamma (IFN-gamma) in vivo, has definite immune activation effect, and discloses the application of the linatide in preparing anti-tumor immune activation medicaments.
(3) The linatide can obviously inhibit the growth of tumors in vivo, obviously prolong the life cycle of tumor-bearing mice, has definite anti-tumor immunotherapy effect, and discloses the application of the linatide in preparing anti-tumor immunotherapy medicaments.
(4) The linatide can obviously inhibit the growth of tumors and obviously prolong the survival period of tumor-bearing mice on a plurality of in vivo animal tumor models, wherein the tumors comprise: the breast cancer, the colon cancer and the melanoma have wide action range, have definite broad-spectrum anti-tumor immunotherapy action, and disclose the wide application value of the linatide in preparing the anti-tumor immunotherapy medicament.
(5) The linatide has the specific effects of inhibiting or delaying metastasis and recurrence in vivo and prolonging the survival period after tumor operation.
(6) Furthermore, it is important that the function of linatide is independent of its existing function, hypoglycemic, because it is tumor-bearing in immunocompromised, normoglycemic mice.
In general, the linatide can be used for preparing a medicine for stimulating immune cell proliferation, the linatide can be used for preparing a medicine for enhancing interferon gamma (IFN-gamma) expression, the linatide can be used for preparing an immune activation medicine, the linatide can be used for preparing an anti-tumor immunotherapy medicine, and the linatide can be used for preparing an anti-tumor medicine. The linatide can be used for preparing medicaments for inhibiting or delaying metastasis recurrence and prolonging the survival period after tumor operation. Moreover, because the tumor is carried on the mice with healthy immunity and normal blood sugar, the function of the linatide is not dependent on the existing function of reducing the blood sugar.
Drawings
FIG. 1 proliferation-stimulating effects of linatide on Peripheral Blood Mononuclear Cells (PBMCs)
FIG. 2 stimulation of IFN- γ secretion by Peripheral Blood Mononuclear Cells (PBMCs) by linatide
FIG. 3 anti-tumor immunotherapeutic Effect of linatide on mouse melanoma model (A) Elispot results (B) Change in tumor volume with time after different treatments (C) Change in survival in mice of different treatment groups
FIG. 4 anti-tumor immunotherapeutic Effect of linatide on mouse Breast cancer model (A) Elispot results (B) Change in tumor volume with time after different treatments (C) Change in survival in mice of different treatment groups
FIG. 5 anti-tumor immunotherapeutic Effect of linatide on mouse Colon cancer model (A) Elispot results (B) Change in tumor volume with time after different treatments (C) Change in survival of mice from different treatment groups
FIG. 6 survival Change in mice of different treatment groups post-operatively in mouse metastatic recurrent Breast cancer model
Detailed Description
Example 1 detection of immune activation function of polypeptide drug on peripheral blood mononuclear cells
First, experiment method
1. Determination of objects to be screened
We searched the drug library of polypeptides using drug bank to exclude FDA-approved polypeptides for infectious disease treatment, hematological disease treatment, tumor treatment and immunomodulation, leaving these polypeptides with approved functions unrelated to tumor treatment and immunomodulation. The functions are focused on the treatment of hormonal imbalance, the treatment of sexual dysfunction, the treatment of diabetes, the treatment of gastrointestinal digestive tract diseases, the treatment of genetic diseases, the treatment of cardiovascular diseases, the cure of bone diseases, the treatment of nervous system diseases, the treatment of respiratory disorders, the treatment of eye disorders and the treatment of malabsorption. This includes polypeptide drugs for the treatment of diabetes. In addition, the specific polypeptide drugs for diabetes treatment on the market in China were also searched. After summarizing FDA and chinese SFDA approved polypeptide drugs for diabetes treatment, we purchased these polypeptides for in vitro and in vivo activity detection and validation of the present invention by various routes. The immune activation function of the polypeptides is screened on peripheral blood mononuclear cells, and the screening finds that the peptide-risperidone for treating the diabetes has stronger immune activation function. The lisinopeptide was obtained from Xenoffy pharmaceutical Co, and was purchased from Nanjing pharmaceutical Co., Ltd. (production lot: 8F347A) and used as it was in a dose form or diluted with PBS.
2. Detection of proliferation-stimulating effect of linatide on Peripheral Blood Mononuclear Cells (PBMC)
Collecting peripheral blood of healthy volunteers under aseptic condition, anticoagulating with heparin, separating Peripheral Blood Mononuclear Cells (PBMC) with lymphocyte separation solution, suspending the cells in RPMI-1640 cell culture medium containing 10% fetal calf serum, and adjusting PBMC cell concentration to 3 × 105Perml, PBMC were plated into 96 well cell plates at 200. mu.l per well, and linatide was added to a final concentration of 1. mu. mol/L and incubated with PBS as a control at 37 ℃ for 72h in 5% CO 2. After 72h, the proliferation of the cells was detected by using Biyun enhanced CCK-8 kit (cat No. C0042).
3. Detection of IFN-gamma stimulated secretion of Peripheral Blood Mononuclear Cells (PBMC) by linatide
Collecting peripheral blood of healthy volunteers under aseptic condition, anticoagulating with heparin, separating Peripheral Blood Mononuclear Cells (PBMC) with lymphocyte separation solution, suspending the cells in RPMI-1640 cell culture medium containing 10% fetal calf serum, and adjusting PBMC cell concentration to 3 × 105Perml, PBMC were plated into 96 well cell plates at 200. mu.l per well, and linatide was added to a final concentration of 1. mu. mol/L and incubated with PBS as a control at 37 ℃ for 72h in 5% CO 2. After 72h, the supernatant was centrifuged and the cells were assayed for IFN-. gamma.stimulated secretion using an ELISA kit from Invitrogen (cat. No. 88-7316-76).
Second, experimental results
The linatide can remarkably stimulate the proliferation of Peripheral Blood Mononuclear Cells (PBMCs). The results in figure 1 show that the CCK-8 kit detects mean absorbance values a450 at 450nm of 0.4908 and 0.7568, respectively, of PBMCs after 72h incubation with PBS control and risperidone treatment, which is approximately 1.6-fold higher than the PBS control, and there is a significant difference between the two groups (P <0.05), and that risperidone is able to significantly stimulate PBMC proliferation. The results of this preliminary demonstration that the linatide has a certain immune activation effect are also quite unexpected, and suggest that the linatide may have potential therapeutic effects for anti-tumor or anti-virus.
The linatide can remarkably stimulate the secretion of IFN-gamma of Peripheral Blood Mononuclear Cells (PBMCs). The results in figure 2 show that the ELISA kit for IFN- γ detects the concentration of IFN- γ in the extracellular supernatant of PBMC after 72h of culture with PBS control and linatide treatments, and that the extracellular IFN- γ concentrations in PBS control and linatide treated groups were 72 and 115pg/ml, respectively, with significant difference between the two groups (P <0.05), indicating that linatide can significantly stimulate PBMC to secrete IFN- γ. The result confirms the previous proliferation stimulation experiment and also indicates that the linatide has a determined immune activation effect, and the result is also greatly unexpected, and the result suggests that the linatide has a potential therapeutic effect for resisting tumors or viruses.
Third, experiment summary
The above results of this example are very interesting, the first time it was detected that linatide had a definite immune activation in vitro, and since the cells were selected from peripheral blood PBMCs of normal healthy volunteers, the immune activation in vitro was not dependent on whether the PBMC source was a type 2 diabetic, i.e. the activity and function of linatide was not dependent on, nor independent of, its existing function. Based on the confirmation of definite immune activation, we will next test the anti-tumor immunotherapy effect on multiple tumor models, and the immune activation effect on in vivo animal models.
Example 2 Observation of the therapeutic Effect of Linasatide on Normal mouse melanoma model
First, experiment method
A normal healthy mouse C57BL/6 is selected, the mouse is immune-competent and is euglycemic, and mainly tumors (melanoma models) are wanted to be born on the immune-competent and euglycemic mouse, and then the treatment effect and the immune activation effect are observed. Because of the tumor bearing capacity of immunocompromised, normoglycemic mice, such function is not dependent on its existing function-hypoglycemic if the linatide is effective.
C57BL/6 mice 6-8 weeks old are selected, and a subcutaneous melanoma model is established in the right axilla. One side of each mouse was inoculated with 5X 106A tumor size of about 200mm was measured after about 6 days for each B16/F10 melanoma cell3The mice were randomly divided into 2 groups of 12 mice each, which were: PBS control group (100. mu.l PBS) and the risperidone subcutaneous injection treatment group (the dose of risperidone is 10. mu.g/kg, the injection volume is 100. mu.l) were injected 1 time per day subcutaneously. The day of initiation of the linatide treatment was recorded as day 0 of dosing, and tumor volumes and mice were weighed prior to linatide and PBS treatment on day 0 of dosing. According to the grouping, the inoculated mice are raised in a clean-grade animal room. In each group, 6 tumors were randomly selected on day 7 of administration, and tumor tissues were subjected to ELISpot assay using mouse Interferon gamma ELISPOT kit (cat # ab64029) from Abcam to detect IFN-. gamma.secretion in tumor tissues. The remaining 6 mice in each group were followed to measure tumor volume and body weight, and the survival time of the mice was recorded (day of survival was the day of tumor bearing). The tumor volume formula is V ═ 0.5 × Length × Width2。
Second, experimental results
IFN-gamma secretion was measured using the Interferon gamma ELISPOT kit after PBS control and rissin subcutaneous injection treatment in a normal mouse melanoma model, and the results in FIG. 3A show that IFN-gamma ELISPOT in PBS control and rissin treatment groups was 171 spots and 414 spots/2X 105Cell, there was a significant difference between the two groups (P)<0.05), the risperidone-treated group was more than 2-fold higher than the control group, compared with the PBS control group, and was able to performRemarkably stimulates the secretion of IFN-gamma. The result not only sufficiently confirms the result of the in vitro immune activation of the linatide, but also can directly indicate that the linatide has a definite immune activation effect in vivo.
The results in fig. 3B show that on the normal mouse melanoma model, the PBS control and the risperidone treatment were injected subcutaneously, and the results at day 6 and day 9 after injection treatment showed that the risperidone-treated group was able to significantly inhibit the increase in tumor subvolume (P < 0.05). The results are consistent with the results of the in vitro and in vivo immune activation function of the aforementioned lixisenatide, and can also directly indicate that the lixisenatide has a definite anti-tumor immunotherapy effect in vivo.
The results in fig. 3C show that in the normal mouse melanoma model, the PBS control group died beginning on day 27 after tumor loading and all died by day 34. However, mice died not beginning until day 31 in the rissin-treated group until all mice died at day 41. Subcutaneous injection of linatide can significantly prolong the survival of melanoma-bearing mice. The results are consistent with the results of the in vitro and in vivo immune activation function of the aforementioned risperidone and the results of the obvious tumor growth inhibition, and can directly indicate that the risperidone has a definite anti-tumor immunotherapy effect in vivo.
Third, experiment summary
The in vivo result of a normal mouse melanoma model shows that the linatide has a definite immune activation effect and an anti-tumor immunotherapy effect, and the anti-tumor effect of the linatide is realized by activating immunity, namely the linatide has a remarkable effect of activating anti-tumor immunity. Moreover, because the tumor is carried on the mice with healthy immunity and normal blood sugar, the function of the linatide is not dependent on the existing function of reducing the blood sugar.
Example 3 observation of the therapeutic Effect of subcutaneous injection of Risinapine on a Normal mouse Breast cancer model
First, experiment method
The female mouse is a normal healthy BALB/c female mouse, the mouse is immune-competent and is euglycemic, the tumor-bearing mouse (breast cancer model) is wanted to be arranged on the immune-competent and euglycemic mouse, and then the treatment effect and the immune activation effect are observed. Because of the tumor bearing capacity of immunocompromised, normoglycemic mice, such function is not dependent on its existing function-hypoglycemic if the linatide is effective.
A BALB/c female mouse with the age of 6-8 weeks is selected to establish a subcutaneous breast cancer model at the right armpit fat pad. One side of each mouse was inoculated with 5X 106Individual mouse 4T1 breast cancer cells, approximately 8 days later, were measured for tumor size to approximately 200mm3The mice were randomly divided into 2 groups of 12 mice each, which were: PBS control group (100. mu.l PBS) and the risperidone subcutaneous injection treatment group (the dose of risperidone is 10. mu.g/kg, the injection volume is 100. mu.l) were injected 1 time per day subcutaneously. The day of initiation of the linatide treatment was recorded as day 0 of dosing, and tumor volumes and mice were weighed prior to linatide and PBS treatment on day 0 of dosing. According to the grouping, the inoculated mice are raised in a clean-grade animal room. In which 6 tumors were randomly selected from each group on day 7, and tumor tissues were subjected to ELISpot assay using Abcam's mouse Interferon gamma ELISPOT kit (cat # ab64029) to detect IFN-. gamma.secretion in tumor tissues. The remaining 6 mice in each group were followed to measure tumor volume and body weight, and the survival time of the mice was recorded (day of survival was the day of tumor bearing). The tumor volume formula is V ═ 0.5 × Length × Width2。
Second, experimental results
The results in FIG. 4A show that IFN-. gamma.secretion was detected using the Interferon gamma ELISPOT kit after PBS control and rissin treatment by subcutaneous injection in a normal mouse breast cancer model, and that IFN-. gamma.ELISPOT was 181 and 314 spots/2X 10 in PBS control and rissin treatment groups, respectively5Cell, there was a significant difference between the two groups (P)<0.05), compared with the PBS control group, the risperidone-treated group is more than 1.7 times of the control group and can remarkably stimulate the secretion of IFN-gamma. The result confirms the result of the in vitro immune activation of the linatide and can directly indicate that the linatide has definite immune activation in vivo.
The results in fig. 4B show that the results at day 9, compared to the control group, after PBS control and risperidone subcutaneous injection treatment on a normal mouse breast cancer model, show that the risperidone-treated group was able to significantly inhibit the increase in tumor volume (P < 0.05). The results are consistent with the results of the in vitro and in vivo immune activation function of the aforementioned lixisenatide, and can also directly indicate that the lixisenatide has a definite anti-tumor immunotherapy effect in vivo.
The results in figure 4C show that in the normal mouse breast cancer model, the PBS control group, mice died beginning on day 25 after tumor loading and all died by day 34. However, mice died not beginning until day 33 in the rissin-treated group until all mice died at day 49. Subcutaneous injection of linatide can significantly prolong the survival of melanoma-bearing mice. The results are consistent with the results of the in vitro and in vivo immune activation function of the aforementioned risperidone and the results of the obvious tumor growth inhibition, and can directly indicate that the risperidone has a definite anti-tumor immunotherapy effect in vivo.
Third, experiment summary
The in vivo result of a normal mouse breast cancer model shows that the linatide has a definite immune activation effect and an anti-tumor immunotherapy effect, and the anti-tumor effect of the linatide is realized by activating immunity, namely the linatide has a remarkable effect of activating anti-tumor immunity. Moreover, because the tumor is carried on the mice with healthy immunity and normal blood sugar, the function of the linatide is not dependent on the existing function of reducing the blood sugar.
Example 4 Observation of the therapeutic Effect of Linfenacin on Normal mouse Colon cancer models
First, experiment method
The female mouse is a normal healthy BALB/c female mouse, the mouse is immune-competent and is euglycemic, the tumor-bearing mouse (colon cancer model) is wanted to be arranged on the immune-competent and euglycemic mouse, and then the treatment effect and the immune activation effect are observed. Because of the tumor bearing capacity of immunocompromised, normoglycemic mice, such function is not dependent on its existing function-hypoglycemic if the linatide is effective.
A BALB/c female mouse with the age of 6-8 weeks is selected to establish a subcutaneous colon cancer model at the right axillary fat pad. One side of each mouse was inoculated with 5X 105Mouse CT26 colon cancer cells, tumor size was measured to about 200mm after about 10 days3The mice were randomly divided into 2 groups of 12 mice each, which were: PBS control group (100. mu.l PBS) and the risperidone subcutaneous injection treatment group (the dose of risperidone is 10. mu.g/kg, the injection volume is 100. mu.l) were injected 1 time per day subcutaneously. According to the grouping, the inoculated mice are raised in a clean-grade animal room. On day 7, 6 of each group were bled and tumor tissues were subjected to ELISpot assay using Abcam's mouse Interferon gamma ELISPOT kit (cat # ab64029) to detect IFN-. gamma.secretion in tumor tissues. The remaining 6 of each group were followed to measure tumor volume, body weight, and mice survival recorded, with the day of starting the treatment with linatide being recorded as day 0, and tumor volumes were measured and weighed before the treatment with linatide and PBS on day 0. The tumor volume formula is V ═ 0.5 × Length × Width2。
Second, experimental results
The results in FIG. 5A show that IFN-. gamma.secretion was detected using the Interferon gamma ELISPOT kit after the PBS control and the rissin peptide were subcutaneously injected in the normal mouse colon cancer model, and that the IFN-. gamma.ELISPOT in the PBS control and the rissin peptide-treated groups was 197 and 305 spots/2X 10, respectively5Cell, there was a significant difference between the two groups (P)<0.05), compared with the PBS control group, the risperidone-treated group is more than 1.5 times of the control group and can remarkably stimulate the secretion of IFN-gamma. The result confirms the result of the in vitro immune activation of the linatide and can directly indicate that the linatide has definite immune activation in vivo.
The results in fig. 5B show that the results at day 6 show that the risperidone-treated group can inhibit the increase in tumor volume and that the tumor volume can be significantly inhibited at day 9 (P <0.05) compared to the control group after PBS control and risperidone subcutaneous injection treatment on a normal mouse colon cancer model. The results are consistent with the results of the in vitro and in vivo immune activation function of the aforementioned lixisenatide, and can also directly indicate that the lixisenatide has a definite anti-tumor immunotherapy effect in vivo.
The results in figure 5C show that on the normal mouse colon cancer model, the PBS control group, mice died beginning on day 23 after tumor loading and all died by day 34. However, mice died not beginning until day 30 in the rissin-treated group until all mice died at day 42. Subcutaneous injection of linatide can significantly prolong the survival of colon cancer tumor-bearing mice. The results are consistent with the results of the in vitro and in vivo immune activation function of the aforementioned risperidone and the results of the obvious tumor growth inhibition, and can directly indicate that the risperidone has a definite anti-tumor immunotherapy effect in vivo.
Third, experiment summary
The in vivo result of a normal mouse colon cancer model shows that the linatide has definite immune activation effect and anti-tumor effect, and the anti-tumor effect of the linatide is realized by activated immunity, namely the linatide has obvious effect of activating anti-tumor immunity. Moreover, because the tumor is carried on the mice with healthy immunity and normal blood sugar, the function of the linatide is not dependent on the existing function of reducing the blood sugar.
Example 5 Observation of the Effect of linatide on postoperative survival in a model of metastatic recurrent Breast cancer in mice
First, experimental methods and materials
1. Experimental materials:
2. 4T1 cell culture
The culture medium of mouse breast cancer 4T1 cells is RPMI-1640 containing 10% fetal calf serum, 100U/ml penicillin and 100 mug/ml streptomycinWhole culture medium, cells at 37 deg.C and CO2The culture was continued in a 5% strength incubator.
Human HCC cell lines BEL-7402, HuH-7, PLC/PRF/5 and SMMC-7721 were purchased from Shanghai national academy of sciences cell banks. Cell line MHCC97H was given by professor Jiafan, a secondary Zhongshan hospital, university of Compound Dan. The culture media of the five HCC cells were DMEM complete medium supplemented with 10% fetal bovine serum. The cells were continuously cultured in a constant temperature incubator at 37 ℃ and a CO2 concentration of 5%.
3. Mouse feeding
The experimental animals are: female SPF-grade BALB/c mice, 6 weeks old, weigh about 20 g. The animal is bred in an SPF animal house, the environment temperature is 22-25 ℃, the relative humidity is 40-60%, the day and night photoperiod is 12:12 hours, and the animal is bred by using autoclaved water and commercial mouse feed.
4. Construction and operation of mammary in-situ metastatic tumor model
Taking 4T1 cells in logarithmic growth phase, digesting with pancreatin, and preparing into cell suspension with concentration of 2 × 106/ml by using PBS; 0.1ml of 4T1 cell suspension is inoculated to the fourth mammary fat pad on the left side of the mouse to construct a mouse mammary orthotopic tumor model. After inoculation is finished, observing the state of the mouse, the infection of the inoculated part and the growth condition of the tumor day by day; the long diameter and the short diameter of the tumor are measured by a vernier caliper, the tumor volume is calculated according to the formula (length multiplied by width 2)/2 and recorded, and a curve is drawn. The mouse body weight was also weighed and recorded.
11 days after 4T1 cells are inoculated, the diameter of the breast in-situ tumor reaches about 5 mm. The mammary tumor tissue of the mice was completely excised under isoflurane gas anesthesia, the adherent mammary fat pad was removed, and the incised skin was sutured. After the surgery was completed, the state of the mice, whether the breast carcinoma had recurred, and the survival time of the mice were observed day by day.
The administration mode comprises the following steps: mice were randomly divided into 2 groups of 6 mice each, which were: PBS control group (100. mu.l PBS) and the risperidone subcutaneous injection treatment group (the dose of risperidone is 10. mu.g/kg, the injection volume is 100. mu.l) were injected 1 time per day subcutaneously. According to the grouping, the inoculated mice are raised in a clean-grade animal room. The first dose was given on day 9 (also 2 days prior to surgery) after tumor loading, followed by 1 subcutaneous injection per day for a total of 20 injections.
Second, experimental results
The results in fig. 6 show that breast cancer removal surgery was performed on day 11 after tumor bearing, followed by subcutaneous injections 1 per day for a total of 20 injections on day 9 after tumor bearing (also 2 days before surgery) on a mouse metastatic recurrent breast cancer model. In the PBS control group, mice died beginning on day 33 after tumor bearing and all mice died by day 44. However, mice died from the rissin-treated group until day 38, and all mice died until day 54. The subcutaneous injection of the risperidone can obviously prolong the postoperative life span of the metastatic recurrent breast cancer tumor-bearing mice.
Third, experiment summary
The result is consistent with the result of the in vitro and in vivo immune activation function of the risperidone and the result of the obvious tumor growth inhibition, and can directly indicate that the risperidone has a definite effect of prolonging the survival period of the metastatic recurrent tumor in vivo.
Summary of the detailed description section:
(1) the linatide can remarkably stimulate the proliferation of immune cells in vitro and remarkably stimulate the secretion and release of interferon gamma (IFN-gamma), has a definite immune activation effect, and discloses the application of the linatide in preparing immune activation medicaments.
(2) The linatide can remarkably stimulate the release of interferon gamma (IFN-gamma) in vivo, has definite immune activation effect, discloses the application of the linatide in preparing immune activation medicaments, and further discloses the application of the linatide in preparing anti-tumor immune activation medicaments.
(3) The linatide can obviously inhibit the growth of tumors in vivo and obviously prolong the life cycle of tumor-bearing mice, has definite anti-tumor immunotherapy effect and discloses the application of the linatide in preparing anti-tumor immunotherapy medicaments.
(4) The linatide can obviously inhibit the growth of tumors and obviously prolong the survival period of tumor-bearing mice on a plurality of in vivo animal tumor models, wherein the tumors comprise: the breast cancer, the colon cancer and the melanoma have wide action range, have definite broad-spectrum anti-tumor immunotherapy action, and disclose the wide application value of the linatide in preparing the anti-tumor immunotherapy medicament.
(5) It is important that the function of linatide is independent of its existing function, hypoglycemic, because it is tumor-bearing in immunocompromised, normoglycemic mice.
(6) The linatide has a definite function of prolonging the survival period of the metastatic recurrent tumor after operation in vivo.
In general, the linatide can be used for preparing a medicine for stimulating immune cell proliferation, the linatide can be used for preparing a medicine for enhancing interferon gamma (IFN-gamma) expression, the linatide can be used for preparing an immune activation medicine, the linatide can be used for preparing an anti-tumor immunotherapy medicine, the linatide can be used for preparing an anti-tumor medicine, and the linatide can be used for preparing a medicine for prolonging the survival period after metastatic recurrent tumor operation. Moreover, because the tumor is carried on the mice with healthy immunity and normal blood sugar, the function of the linatide is not dependent on the existing function of reducing the blood sugar.
Claims (10)
1. The linatide is used for preparing immune activation medicaments.
2. The use of the linatide of claim 1 for the preparation of a medicament for immune activation, characterized in that said immune activation comprises stimulation of immune cell expansion or promotion of the expression and secretion of interferon gamma.
3. The use of the linatide of claim 1 for the preparation of an immunoactivation medicament, characterized in that said immunoactivation is an antitumor immunoactivation.
4. Application of linatide in preparing antitumor drugs is provided.
5. The use of the linatide of claim 4 in the preparation of anti-tumor medicaments, characterized in that the tumors comprise breast cancer, colon cancer and melanoma.
6. Application of linatide in preparation of tumor immunotherapy drugs.
7. Use of the linatide of claim 6 in the preparation of a medicament for the immunotherapy of tumors, characterized in that said tumors comprise breast cancer, colon cancer and melanoma.
8. Application of linatide in preparation of drugs for controlling or delaying postoperative recurrence of tumors.
9. Application of linatide in preparation of medicine for prolonging postoperative life of tumor is provided.
10. Use of the lisinopeptide according to claim 9 for the preparation of a medicament for prolonging the post-operative survival of a tumor, wherein the tumor is a metastatic recurrent tumor.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011028623.1A CN112121152B (en) | 2020-09-25 | 2020-09-25 | Application of linatide in preparation of antitumor drugs |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011028623.1A CN112121152B (en) | 2020-09-25 | 2020-09-25 | Application of linatide in preparation of antitumor drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112121152A true CN112121152A (en) | 2020-12-25 |
CN112121152B CN112121152B (en) | 2021-06-22 |
Family
ID=73840988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011028623.1A Active CN112121152B (en) | 2020-09-25 | 2020-09-25 | Application of linatide in preparation of antitumor drugs |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112121152B (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107074820A (en) * | 2014-07-25 | 2017-08-18 | 赛尔基因第二国际有限公司 | The new receptor modulators of GLP 1 |
US20180117026A1 (en) * | 2015-03-20 | 2018-05-03 | Deuterx, Llc | Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disorders |
CN108066762A (en) * | 2016-11-07 | 2018-05-25 | 赫兰 | The purposes of GLP-1 receptor stimulating agents and biguanides |
CN108778309A (en) * | 2016-01-26 | 2018-11-09 | 防御素治疗学公司 | The method for adjusting intestinal microbiota |
CN110582268A (en) * | 2017-03-22 | 2019-12-17 | Amw公司 | extruded depot dosage forms for sustained release of active ingredients |
CN110997692A (en) * | 2017-06-02 | 2020-04-10 | 波涛生命科学有限公司 | Oligonucleotide compositions and methods of use thereof |
CN111372969A (en) * | 2017-11-20 | 2020-07-03 | 瑞比奥科技公司 | Composition comprising a metal oxide and a metal oxide |
CN111448207A (en) * | 2017-11-08 | 2020-07-24 | Ionis制药公司 | Oligonucleotide conjugated with G L P-1receptor ligand moiety and use thereof |
WO2020160518A1 (en) * | 2019-02-01 | 2020-08-06 | Memorial Sloan Kettering Cancer Center | Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker |
-
2020
- 2020-09-25 CN CN202011028623.1A patent/CN112121152B/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107074820A (en) * | 2014-07-25 | 2017-08-18 | 赛尔基因第二国际有限公司 | The new receptor modulators of GLP 1 |
US20180117026A1 (en) * | 2015-03-20 | 2018-05-03 | Deuterx, Llc | Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disorders |
CN108778309A (en) * | 2016-01-26 | 2018-11-09 | 防御素治疗学公司 | The method for adjusting intestinal microbiota |
CN108066762A (en) * | 2016-11-07 | 2018-05-25 | 赫兰 | The purposes of GLP-1 receptor stimulating agents and biguanides |
CN110582268A (en) * | 2017-03-22 | 2019-12-17 | Amw公司 | extruded depot dosage forms for sustained release of active ingredients |
CN110997692A (en) * | 2017-06-02 | 2020-04-10 | 波涛生命科学有限公司 | Oligonucleotide compositions and methods of use thereof |
CN111448207A (en) * | 2017-11-08 | 2020-07-24 | Ionis制药公司 | Oligonucleotide conjugated with G L P-1receptor ligand moiety and use thereof |
CN111372969A (en) * | 2017-11-20 | 2020-07-03 | 瑞比奥科技公司 | Composition comprising a metal oxide and a metal oxide |
WO2020160518A1 (en) * | 2019-02-01 | 2020-08-06 | Memorial Sloan Kettering Cancer Center | Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker |
Non-Patent Citations (1)
Title |
---|
SCOTT R DRAB等: ""Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy"", 《CURRENT DIABETES REVIEWS》 * |
Also Published As
Publication number | Publication date |
---|---|
CN112121152B (en) | 2021-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101072875B (en) | Novel cancer antigen peptide and the use thereof | |
EP2839291B1 (en) | Multivalent breast cancer vaccine | |
CN110214144B (en) | Polypeptides and uses thereof | |
US11213563B2 (en) | Polypeptide and use thereof | |
CN114129711B (en) | Application of dolapride in preparing antitumor drugs | |
CN112121152B (en) | Application of linatide in preparation of antitumor drugs | |
CN109923121B (en) | Polypeptide and application thereof | |
Kohchi et al. | Utilization of macrophages in anticancer therapy: the macrophage network theory | |
CN105254744B (en) | The heterogenous expression of polypeptide XZZ-5 and its enhancing CIK cell kill the application in tumor activity | |
CN114177276A (en) | Application of benaludin in preparing tumor immunotherapy medicine | |
CN111744004B (en) | Application of albiglutide in preparing anti-tumor immune activation and tumor immunotherapy medicine | |
CN112587656A (en) | Application of polyethylene glycol loxapine in preparation of antitumor drugs | |
CN110167956B (en) | Polypeptide and application thereof | |
CN115850377A (en) | Tumor neoantigen polypeptide based on NRAS gene Q61K mutation and application thereof | |
CN110448681B (en) | Combined medicine for malignant tumor immunotherapy | |
US11396528B2 (en) | Polypeptide and use thereof | |
CN110672855B (en) | Use of actin-binding protein 2 in screening of medicaments for treating smooth muscle dysfunction diseases | |
CN113181351A (en) | Individual tumor therapeutic vaccine and preparation method thereof | |
CN110072876B (en) | Polypeptide and application thereof | |
CA2832376A1 (en) | Drug containing recombinant mistletoe lectins for treating malignant melanoma | |
CN102838679B (en) | The preparation and application of Her2 neu antigen positive tumor therapeutic vaccines | |
CN101670098B (en) | Application of restructured thymosin alpha source in preparation of medicine for preventing and treating fatty liver | |
CN111789939A (en) | Application of liraglutide in preparation of tumor immunotherapy medicine | |
CN108409866A (en) | A kind of multi-epitope combined peptide for treating and preventing human papilloma virus infection and relevant disease | |
CN106117338B (en) | HLA-A0201-restricted CTL epitope of cytokeratin 19 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |